Whitepaper zur Auswahl eines strategischen Partners für die Auslagerung von Artwork und Labelling in der D‑A‑CH-Region Wertsteigerung und Risikominderung durch Auslagerung an ein Fachunternehmen – ein Whitepaper zu bewährten Verfahren

Advanced Artwork and Labelling Production Analytics White Paper Pharmaceutical Artwork Departments can accelerate business impact with Advanced Artwork and Labelling Production Analytics (AALPA)

Selecting a Strategic Outsourcing Artwork and Labelling Partner White Paper Enhancing Value and Mitigating Risk by Outsourcing to A Subject Matter Expert Organisation – A Best Practice White Paper

Due to COVID-19, auditing as we know it is changing. In-person audits are increasingly being replaced by remote audits. Read our guide to a successful remote audit.

Your company celebration and kudos does not last long as someone spots an artwork issue. In other words: here comes the recall. Yes, the worst-case scenario. We guess you won't sleep very well until this nightmare is over. If you are looking for fully compliant and error-free pharma artworks to hit the market efficiently while reducing your stress levels, keep an eye on the following four most common pharma artwork hurdles: One: Artwork process problems: Outdated and inefficient manual systems, systematic errors, inconsistencies, process gaps... all of them will develop into artwork errors. Too many assets, too many emails, too many people. Two: Compliance burdens: Labelling needs to be compliant with local regulations and current Good Manufacturing Practice, and this is probably the biggest concern for pharma companies. As these two become more and more complex over time, we need to ensure not only our company is fully aligned but also all the suppliers we use to go to market. Three: Speed issues: After the artwork change is agreed, there is a rush to go to market as soon as possible. Every day that passes without the product on the shelfs results in losses for the company. But working under huge pressure is when mistakes are more likely to happen. Four: Quality issues: Sometimes errors do not necessitate a recall, but they are still quality defects. Even though you don't have to start a recall, there can be potential quality control issues throughout the artwork process, and each of them have to be taken seriously. So, how to avoid these common pharma artwork hurdles? Pharma companies need to keep full control of their end-to-end artwork processes, making sure they are building quality into them. Reducing the risk of errors at every stage, ensuring they are 100% GMP compliant, and managing interactions and communications with stakeholders and suppliers are the key priorities. How to achieve that depends on the company, but one of the best ways today is through an Artwork Management System (AMS). Many of these are specifically designed for pharma companies to drive quality, security and GMP compliance while bringing better visibility to the full end-to-end artwork process. Top pharma companies are choosing GLAMS, (Global Artwork Management System), Perigord's pharma focused AMS, enables you to gain full control over your artwork processes, avoid hurdles, align with the industry regulations and thus improve your business results.

Join us and your industry peers for our latest Webinar "How the power of a connected AMS and automated proofreading solution will improve the efficiencies of your process and increase your speed to market" on-demand now where experts from Dr. Pfleger Arzneimittel GmbH, Perigord and Schlafender Hase will share their experience and demonstrate how having an AMS system with integrated digital comparison functionality will increase your speed to market, reduce the risk of product recall, and provide a full end-to-end audit trail of all approvals.

Perigord Life Science Solutions is delighted to announce we are joining Orphan Drug Consulting to bring you this latest Webinar, "Launching an RX Product in the EU – Fail to Prepare, Prepare to Fail," with our panel of speakers covering the different packaging and artwork requirements to launch a product in Europe, along with the key regulatory differences between the US and EU regulatory bodies, the launch process and more.

Join our subject matter experts on our latest webinar who will map out the packaging artwork and labelling journey from late stage 2 clinical trials to commercialisation and beyond. This webinar will chart a course through the complexities you will face as you prepare your product for the market. Reserve your seat: